Zhou Xiao-Hui, Liang Jin-Hua, Wang Li, Zhu Hua-Yuan, Wu Jia-Zhu, Xia Yi, Li Yue, Qin Shu-Chao, Fan Lei, Li Jian-Yong, Xu Wei
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China.
J Cancer. 2020 Jun 21;11(17):4980-4988. doi: 10.7150/jca.37484. eCollection 2020.
Mantle cell lymphoma (MCL) is a distinct subtype of B cell non-Hodgkin lymphoma. No research has yet documented to investigate the prognostic implications of Epstein-Barr virus (EBV) infection in MCL. The objective of this study was to determine whether EBV DNA load may influence the heterogeneity in the course of the disease in MCL patients. Eighty-eight MCL patients were retrospectively enrolled in the study. EBV DNA load was detected by real-time quantitative PCR for quantification. The univariate and multivariate Cox proportional hazards models were established for the estimation of prognostic factors. Twenty-seven patients were detected positive for EBV DNA and the median virus titer was 1.72×10 copies/mL (range, 8.20×10 to 4.14×10 copies/mL). With a median follow-up of 39 months (range, 9 to 120 months), patients in EBV DNA-positive group displayed unfavorable progression-free survival (PFS) (=0.012) and overall survival (OS) (=0.004) than patients in EBV DNA-negative group. Multivariate Cox regression analysis revealed that EBV DNA-positivity was an independent risk factor for both PFS (HR, 2.04; 95% CI, 1.07 to 3.92; =0.031) and OS (HR, 2.68; 95% CI, 1.20 to 6.00; =0.016). Reduction in EBV copies was significantly associated with therapy-response. Circulating EBV DNA load in whole blood proved to be a significant predictor of prognosis in patients with MCL, which needs further validation in large-scale clinical studies.
套细胞淋巴瘤（MCL）是B细胞非霍奇金淋巴瘤的一种独特亚型。尚无研究记录调查爱泼斯坦-巴尔病毒（EBV）感染在MCL中的预后意义。本研究的目的是确定EBV DNA载量是否可能影响MCL患者疾病进程中的异质性。88例MCL患者被回顾性纳入研究。通过实时定量PCR检测EBV DNA载量进行定量。建立单变量和多变量Cox比例风险模型以评估预后因素。27例患者EBV DNA检测呈阳性，病毒滴度中位数为1.72×10拷贝/mL（范围为8.20×10至4.14×10拷贝/mL）。中位随访39个月（范围为9至120个月），EBV DNA阳性组患者的无进展生存期（PFS）（=0.012）和总生存期（OS）（=0.004）均比EBV DNA阴性组患者差。多变量Cox回归分析显示，EBV DNA阳性是PFS（HR，2.04；95%CI，1.07至3.92；=0.031）和OS（HR，2.68；95%CI，1.20至6.00；=0.016）的独立危险因素。EBV拷贝数减少与治疗反应显著相关。全血中循环EBV DNA载量被证明是MCL患者预后的重要预测指标，这需要在大规模临床研究中进一步验证。
